Low-Dose Aspirin Reduces Recurrence in PI3K-Altered Colorectal Cancer

Summary of Research on Aspirin and PI3K Pathway Alterations in Colorectal Cancer

This text details a clinical trial investigating the effect of aspirin on colorectal cancer (CRC) recurrence in patients with specific genetic alterations in the PI3K pathway. Here’s a breakdown of the key findings:

Study Design:

* Participants: 1103 patients with stage I-III rectal or stage II-III colon cancer harboring somatic alterations in PI3K pathway genes.
* Groups: Patients were divided into two groups based on PIK3CA mutations:
* Group A: Specific hotspot mutations in exon 9 or 20 of Pik3ca.
* group B: Other moderate- or high-impact variants in Pik3ca, Pik3r1, or PTEN.
* Intervention: randomized, double-blind, placebo-controlled trial comparing 160mg of aspirin daily to a placebo for 3 years.

Key Findings:

* Recurrence Rates (Group A): Aspirin reduced the 3-year cumulative incidence of recurrence to 7.7% compared to 14.1% with placebo (HR 0.49, 95% CI 0.24-0.98, P* = 0.04).
* recurrence Rates (Group B): Aspirin also reduced recurrence in Group B to 7.7% vs 16.8% with placebo (HR 0.42,95% CI 0.21-0.83).
* Disease-Free Survival: Aspirin improved 3-year disease-free survival in both groups:
* Group A: 88.5% with aspirin vs 81.4% with placebo (HR 0.61,95% CI 0.34-1.08).
* Group B: 89.1% with aspirin vs 78.7% with placebo (HR 0.51, 95% CI 0.29-0.88).
* Adverse Events: Severe adverse events were more common in the aspirin group (16.8%) compared to the placebo group (11.6%).

* the study suggests that aspirin may be a beneficial adjunct therapy for patients with CRC who have alterations in the *PI3K pathway.
* The findings coudl possibly influence global guidelines for treating colon and rectal cancer.
* Testing biopsy specimens for PI3K pathway gene alterations before treatment (especially neoadjuvant therapy for rectal cancer) is recommended.

Limitations:

* The patient population may have been healthier than the general CRC population.
* Genomic data was missing for a notable number of patients (803), especially those with rectal cancer.
* Patients who received neoadjuvant therapy for rectal cancer appeared to benefit from aspirin, suggesting a need for further examination in this subgroup.

In essence, this research provides evidence that personalized treatment based on genetic facts (specifically PI3K pathway alterations) combined with aspirin could improve outcomes for CRC patients.